Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A high resolution LC-MS targeted method for the concomitant analysis of 11 contraceptive progestins and 4 steroids.

Laszlo CF, Paz Montoya J, Shamseddin M, De Martino F, Beguin A, Nellen R, Bruce SJ, Moniatte M, Henry H, Brisken C.

J Pharm Biomed Anal. 2019 Oct 25;175:112756. doi: 10.1016/j.jpba.2019.07.004. Epub 2019 Jul 25.

2.

C/EBPα mediates the growth inhibitory effect of progestins on breast cancer cells.

Nacht AS, Ferrari R, Zaurin R, Scabia V, Carbonell-Caballero J, Le Dily F, Quilez J, Leopoldi A, Brisken C, Beato M, Vicent GP.

EMBO J. 2019 Sep 16;38(18):e101426. doi: 10.15252/embj.2018101426. Epub 2019 Aug 2.

PMID:
31373033
3.

Two-Tier Mapper, an unbiased topology-based clustering method for enhanced global gene expression analysis.

Jeitziner R, Carrière M, Rougemont J, Oudot S, Hess K, Brisken C.

Bioinformatics. 2019 Sep 15;35(18):3339-3347. doi: 10.1093/bioinformatics/btz052.

PMID:
30753284
4.

Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.

Fiche M, Scabia V, Aouad P, Battista L, Treboux A, Stravodimou A, Zaman K; RLS, Dormoy V, Ayyanan A, Sflomos G, Brisken C.

J Pathol. 2019 Mar;247(3):287-292. doi: 10.1002/path.5200. Epub 2018 Dec 27.

5.

Oestrogen receptor α AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium.

Cagnet S, Ataca D, Sflomos G, Aouad P, Schuepbach-Mallepell S, Hugues H, Krust A, Ayyanan A, Scabia V, Brisken C.

Nat Commun. 2018 Nov 9;9(1):4723. doi: 10.1038/s41467-018-07175-0.

6.

The challenges of modeling hormone receptor-positive breast cancer in mice.

Özdemir BC, Sflomos G, Brisken C.

Endocr Relat Cancer. 2018 May;25(5):R319-R330. doi: 10.1530/ERC-18-0063. Epub 2018 Mar 21. Review.

PMID:
29563191
7.

In vivo reprogramming of non-mammary cells to an epithelial cell fate is independent of amphiregulin signaling.

George AL, Boulanger CA, Anderson LH, Cagnet S, Brisken C, Smith GH.

J Cell Sci. 2017 Jun 15;130(12):2018-2025. doi: 10.1242/jcs.200030. Epub 2017 Apr 28.

8.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

9.

Adamts18 deletion results in distinct developmental defects and provides a model for congenital disorders of lens, lung, and female reproductive tract development.

Ataca D, Caikovski M, Piersigilli A, Moulin A, Benarafa C, Earp SE, Guri Y, Kostic C, Arsenijevic Y, Soininen R, Apte SS, Brisken C.

Biol Open. 2016 Nov 15;5(11):1585-1594. doi: 10.1242/bio.019711.

10.
11.

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.

Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, Vilo J, Ayyanan A, Brisken C.

Cancer Cell. 2016 Mar 14;29(3):407-422. doi: 10.1016/j.ccell.2016.02.002. Epub 2016 Mar 3.

12.

Corrigendum: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.

Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Lefort K, Dotto GP.

Nat Cell Biol. 2015 Oct;17(10):1370. doi: 10.1038/ncb3242. No abstract available.

PMID:
26419803
13.

Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.

Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Lefort K, Dotto GP.

Nat Cell Biol. 2015 Sep;17(9):1193-204. doi: 10.1038/ncb3228. Epub 2015 Aug 24. Erratum in: Nat Cell Biol. 2015 Oct;17(10):1370.

14.

Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis.

Brisken C, Hess K, Jeitziner R.

Endocrinology. 2015 Oct;156(10):3442-50. doi: 10.1210/en.2015-1392. Epub 2015 Aug 4. Review.

15.

Endocrine hormones and local signals during the development of the mouse mammary gland.

Brisken C, Ataca D.

Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):181-95. doi: 10.1002/wdev.172. Epub 2015 Jan 23. Review.

PMID:
25645332
16.

Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk.

Rajaram RD, Buric D, Caikovski M, Ayyanan A, Rougemont J, Shan J, Vainio SJ, Yalcin-Ozuysal O, Brisken C.

EMBO J. 2015 Mar 4;34(5):641-52. doi: 10.15252/embj.201490434. Epub 2015 Jan 20.

17.

An ex vivo model to study hormone action in the human breast.

Sflomos G, Shamsheddin M, Brisken C.

J Vis Exp. 2015 Jan 8;(95):e52436. doi: 10.3791/52436.

18.

Reply to Is progesterone a neutral or protective factor for breast cancer?

Brisken C.

Nat Rev Cancer. 2014 Feb;14(2):146. doi: 10.1038/nrc3518-c2. Epub 2014 Jan 20. No abstract available.

PMID:
24442144
19.

A new Achilles Heel in breast cancer?

Sflomos G, Brisken C.

Oncotarget. 2013 Aug;4(8):1126-7. No abstract available.

20.

Monitoring proliferative activities of hormone-like odorants in human breast cancer cells by gene transcription profiling and electrical impedance spectroscopy.

Pick H, Terrettaz S, Baud O, Laribi O, Brisken C, Vogel H.

Biosens Bioelectron. 2013 Dec 15;50:431-6. doi: 10.1016/j.bios.2013.06.052. Epub 2013 Jul 4.

PMID:
23896523
21.

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.

Brisken C.

Nat Rev Cancer. 2013 Jun;13(6):385-96. doi: 10.1038/nrc3518. Review.

PMID:
23702927
22.

Does cancer start in the womb? altered mammary gland development and predisposition to breast cancer due to in utero exposure to endocrine disruptors.

Soto AM, Brisken C, Schaeberle C, Sonnenschein C.

J Mammary Gland Biol Neoplasia. 2013 Jun;18(2):199-208. doi: 10.1007/s10911-013-9293-5. Epub 2013 May 24. Review.

23.

Progesterone/RANKL is a major regulatory axis in the human breast.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C.

Sci Transl Med. 2013 Apr 24;5(182):182ra55. doi: 10.1126/scitranslmed.3005654.

24.

miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.

Cimino D, De Pittà C, Orso F, Zampini M, Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, Ponzone R, Romualdi C, Brisken C, De Bortoli M, Biglia N, Provero P, Lanfranchi G, Taverna D.

FASEB J. 2013 Mar;27(3):1223-35. doi: 10.1096/fj.12-214692. Epub 2012 Dec 11.

25.

ER and PR signaling nodes during mammary gland development.

Tanos T, Rojo L, Echeverria P, Brisken C.

Breast Cancer Res. 2012 Jul 19;14(4):210. doi: 10.1186/bcr3166. Review.

26.

ID4 regulates mammary gland development by suppressing p38MAPK activity.

Dong J, Huang S, Caikovski M, Ji S, McGrath A, Custorio MG, Creighton CJ, Maliakkal P, Bogoslovskaia E, Du Z, Zhang X, Lewis MT, Sablitzky F, Brisken C, Li Y.

Development. 2011 Dec;138(23):5247-56. doi: 10.1242/dev.069203.

27.

Paracrine signaling by progesterone.

Rajaram RD, Brisken C.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):80-90. doi: 10.1016/j.mce.2011.09.018. Epub 2011 Sep 16. Review.

PMID:
21945477
28.

Perinatal exposure to bisphenol a increases adult mammary gland progesterone response and cell number.

Ayyanan A, Laribi O, Schuepbach-Mallepell S, Schrick C, Gutierrez M, Tanos T, Lefebvre G, Rougemont J, Yalcin-Ozuysal O, Brisken C.

Mol Endocrinol. 2011 Nov;25(11):1915-23. doi: 10.1210/me.2011-1129. Epub 2011 Sep 8.

29.

High hopes for RANKL: will the mouse model live up to its promise?

Tanos T, Brisken C.

Breast Cancer Res. 2011 Jan 28;13(1):302. doi: 10.1186/bcr2805.

30.

Hormone action in the mammary gland.

Brisken C, O'Malley B.

Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a003178. doi: 10.1101/cshperspect.a003178. Epub 2010 Aug 25. Review.

31.

Control of hair follicle cell fate by underlying mesenchyme through a CSL-Wnt5a-FoxN1 regulatory axis.

Hu B, Lefort K, Qiu W, Nguyen BC, Rajaram RD, Castillo E, He F, Chen Y, Angel P, Brisken C, Dotto GP.

Genes Dev. 2010 Jul 15;24(14):1519-32. doi: 10.1101/gad.1886910.

32.

Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA.

Stem Cells. 2010 Aug;28(8):1435-45. doi: 10.1002/stem.467.

33.

Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression.

Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV.

Mol Cell Biol. 2010 Jun;30(12):3111-25. doi: 10.1128/MCB.01398-09. Epub 2010 Apr 19.

34.

Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates.

Yalcin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Brisken C.

Cell Death Differ. 2010 Oct;17(10):1600-12. doi: 10.1038/cdd.2010.37. Epub 2010 Apr 9.

35.

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.

Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2989-94. doi: 10.1073/pnas.0915148107. Epub 2010 Jan 28.

36.

Stem cells in chemical carcinogenesis.

Dietrich C, Weiss C, Bockamp E, Brisken C, Roskams T, Morris R, Oesch-Bartlomowicz B, Oesch F.

Arch Toxicol. 2010 Mar;84(3):245-51. doi: 10.1007/s00204-009-0491-2. Epub 2009 Nov 26. No abstract available.

PMID:
19941131
37.

Amphiregulin mediates self-renewal in an immortal mammary epithelial cell line with stem cell characteristics.

Booth BW, Boulanger CA, Anderson LH, Jimenez-Rojo L, Brisken C, Smith GH.

Exp Cell Res. 2010 Feb 1;316(3):422-32. doi: 10.1016/j.yexcr.2009.11.006. Epub 2009 Nov 12.

38.

From normal cell types to malignant phenotypes.

Yalcin-Ozuysal O, Brisken C.

Breast Cancer Res. 2009;11(6):306. doi: 10.1186/bcr2418. Epub 2009 Nov 9.

39.

The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.

Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG.

Cell. 2009 Sep 18;138(6):1083-95. doi: 10.1016/j.cell.2009.06.048.

40.

What signals operate in the mammary niche?

Tanos T, Brisken C.

Breast Dis. 2008;29:69-82.

PMID:
19029626
41.

Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation.

Barbaroux JB, Beleut M, Brisken C, Mueller CG, Groves RW.

J Immunol. 2008 Jul 15;181(2):1103-8.

42.

The epithelial-mesenchymal transition generates cells with properties of stem cells.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.

Cell. 2008 May 16;133(4):704-15. doi: 10.1016/j.cell.2008.03.027.

43.

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE.

Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100.

44.
45.

An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells.

Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD.

Breast Cancer Res. 2007;9(3):R38.

46.

Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development.

Ciarloni L, Mallepell S, Brisken C.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5455-60. Epub 2007 Mar 16.

47.

Alveolar and lactogenic differentiation.

Brisken C, Rajaram RD.

J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):239-48. Review.

PMID:
17111223
48.

Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism.

Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, Brisken C.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804. Epub 2006 Feb 24.

49.

Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland.

Mallepell S, Krust A, Chambon P, Brisken C.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2196-201. Epub 2006 Feb 1.

50.

p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation.

Devgan V, Mammucari C, Millar SE, Brisken C, Dotto GP.

Genes Dev. 2005 Jun 15;19(12):1485-95.

Supplemental Content

Loading ...
Support Center